Madrid – A major international study has found that clopidogrel, a widely prescribed blood thinner, is more effective than aspirin in reducing the risk of heart attacks and strokes — without adding extra risk of bleeding. The findings could transform treatment guidelines for millions of patients worldwide.
A Challenge to Decades of Practice
For decades, low-dose aspirin has been the go-to medication for patients with coronary artery disease (CAD), the most common form of heart disease. By thinning the blood, aspirin lowers the chances of blockages that can lead to heart attacks or strokes.
But new research presented at the European Society of Cardiology congress in Madrid and published in The Lancet suggests clopidogrel offers superior protection.
Key Findings
- Analysis of nearly 29,000 patients with CAD across seven clinical trials showed clopidogrel users had a 14% lower risk of major cardiovascular events compared with aspirin users.
- These events included heart attacks, strokes, or cardiovascular-related deaths.
- Crucially, the study found no increase in major bleeding risk, a concern that had previously limited clopidogrel’s broader use.
Professor Anupam Bhardwaj and colleagues noted:
“This comprehensive synthesis shows that long-term clopidogrel monotherapy offers superior protection compared with aspirin, without excess bleeding risk.”
Why It Matters
CAD affects more than 300 million people worldwide, including 2.3 million in the UK. It often requires lifelong medication. Aspirin has traditionally been prescribed indefinitely, but its long-term benefits have been questioned.
The new study suggests that clopidogrel — already widely available in generic form — could become the preferred long-term treatment.
Expert Reactions
Prof Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, said:
“This research suggests that clopidogrel might be more effective at preventing recurrent heart attack or stroke. Importantly, these benefits come without greater risk of major bleeding. These findings are likely to impact how doctors prescribe medication in future.”
What’s Next
The results support a shift in global treatment standards, but experts say further studies on cost-effectiveness and population-wide outcomes will be essential. If adopted, clopidogrel could replace aspirin as the standard therapy for patients with stable CAD, reshaping cardiovascular care worldwide.
Source: The Guardian / The Lancet
Image Credit: Respective Owner
